CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.

Bloomer, Hanan; Khirallah, Jennifer; Li, Yamin; Xu, Qiaobing

Bloomer, Hanan; Khirallah, Jennifer; Li, Yamin; Xu, Qiaobing.

Afiliación

Bloomer H; Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA; School of Medicine and Graduate School of Biomedical Sciences, Tufts University, Boston, MA 02111, USA.
Khirallah J; Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
Li Y; Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA. Electronic address: Yamin.Li@tufts.edu.
Xu Q; Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA. Electronic address: Qiaobing.Xu@tufts.edu.

Adv Drug Deliv Rev ; 181: 114087, 2022 02.

Article en En | MEDLINE | ID: mdl-34942274

Asunto(s)

Sistemas CRISPR-Cas/genética; Edición Génica/métodos; Genoma/genética; Ribonucleoproteínas/metabolismo; Animales; Sistemas de Liberación de Medicamentos/métodos; Epigenoma/genética

Palabras clave

CRISPR/Cas9; Drug delivery systems; Epigenome editing; Gene therapy; Genome editing; RNP

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Ribonucleoproteínas / Genoma / Sistemas CRISPR-Cas / Edición Génica Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google